Leap Therapeutics, LPTX

HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)
Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) from Buy to Neutral. Analyst Price Forecast Suggests 1,441.50% Upside As of January 28,
Leap Therapeutics Inc (LPTX) Stock: A Deeper Look at Its True Potential
Leap Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -70.45%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified pressure on LPTX shares,
Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report)
Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%
Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy.
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...
The Pharma Letter1d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...
BioWorld2d
CRC yes, gastric no in Leap’s sirexatamab phase IIs
Some favorable and some not-so-great results from separate midstage trials testing the anti-dickkopf homolog 1 antibody sirexatamab in combo regimens for two types of gastrointestinal tumors vexed ...
Morningstar24d
Leap Therapeutics Inc LPTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Leap reports positive colorectal cancer study results
CAMBRIDGE, Mass. - Leap Therapeutics, Inc. (NASDAQ:LPTX), a clinical-stage biotech company with a market capitalization of $86 million and an overall "Fair" financial health rating according to ...